Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.

Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.

BACKGROUND: Uncertainty surrounds the correct dosing of lopinavir/r (LPV/r) in HIV-infected children not receiving non-nucleoside reverse transcriptase inhibitors. The licensed total daily dose is 460 mg/m², whereas the original study, reporting excellent viral load (VL) suppression, used a higher 6...

Full description

Bibliographic Details
Main Authors:	Donegan, K, Doerholt, K, Judd, A, Lyall, H, Menson, E, Butler, K, Tookey, P, Riordan, A, Shingadia, D, Tudor-Williams, G, Gibb, D, Walker, A
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy.
by: Doerholt, K, et al.
Published: (2006)

Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
by: Lee, K, et al.
Published: (2007)

The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
by: Donegan, K, et al.
Published: (2012)

Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.
by: Kekitiinwa, A, et al.
Published: (2008)

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.
by: Walker, A, et al.
Published: (2004)

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.
by: Menson, E, et al.
Published: (2006)

Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children
by: Kekitiinwa, A, et al.
Published: (2016)

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
by: Musiime, V, et al.
Published: (2014)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
by: Kityo, C, et al.
Published: (2010)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, M.D., et al.
Published: (2011-05-01)

Clinical trials in children.
by: Menson, E, et al.
Published: (2004)

Childhood Hemolytic Uremic Syndrome, United Kingdom and Ireland
by: Richard M. Lynn, et al.
Published: (2005-04-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, et al.

News coverage of suicidal behavior in the United Kingdom and the Republic of Ireland
by: Marzano, L, et al.
Published: (2018)

Genomic diagnosis of rare pediatric disease in the United Kingdom and Ireland
by: Wright, CF, et al.
Published: (2023)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
by: Gilks, C, et al.
Published: (2012)

Libraries in the United Kingdom and the Republic of Ireland 1998
by: Library Association (London)
Published: (1997)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008-09-01)

Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
by: Mitesh Patel, et al.
Published: (2014-04-01)

Enhanced Eryptosis Following Exposure to Lopinavir
by: Rosi Bissinger, et al.
Published: (2015-12-01)

Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)

The United Kingdom and Ireland experience of the Haemodialysis Reliable Outflow graft for vascular access
by: Hunter, J, et al.
Published: (2018)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
by: Santerre Henriksen A, et al.
Published: (2018-08-01)

Percutaneous device closure of paravalvular leak: combined experience from the United Kingdom and Ireland
by: Calvert, P, et al.
Published: (2016)

Protease Inhibitor Anti-HIV, Lopinavir, Impairs Placental Endocrine Function
by: Camille Fraichard, et al.
Published: (2021-01-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
Published: (2013-01-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Impact of different pack sizes of paracetamol in the United Kingdom and Ireland on intentional overdoses: a comparative study.
by: Hawton, K, et al.
Published: (2011)

Using social media to measure impacts of named storm events in the United Kingdom and Ireland
by: M. Spruce, et al.
Published: (2020-01-01)

Neonatal stroke surveillance study protocol in the United Kingdom and Republic of Ireland
by: Kwok T’ng Chang, et al.
Published: (2022-09-01)

United Kingdom: Citizenship education in the United Kingdom: Comparing England, Northern Ireland, Scotland and Wales
by: Lee Jerome, et al.
Published: (2022-12-01)

Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
by: German, P, et al.
Published: (2009)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
by: D. Zanon, et al.
Published: (2020-12-01)

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
by: Seni Kouanda, et al.
Published: (2020-06-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)